Mylan $60 Million Securities Settlement, Did You Lose Money on Mylan Stock Due to Quality Control Fraud Allegations?

Mylan N.V. — now operating as Viatris Inc. — and several former executives agreed to pay $60 million to settle a securities class action lawsuit alleging the company manipulated quality control measures at its Morgantown, West Virginia manufacturing facility and misled shareholders about the integrity of those systems. Investors who purchased or acquired Mylan N.V. common stock during the class period and suffered resulting losses may qualify for a cash payment. This settlement is in its early stages — specific claim deadlines have not yet been published. Visit mylansecuritieslitigation.com frequently for updates.

Quick Facts

Current Status and What Happens Next

• Preliminary approval pending — investors filed for preliminary approval on February 19, 2026, following a December 2025 mediation. The court has not yet ruled on preliminary approval. All claim deadlines, opt-out deadlines, and hearing dates remain TBD.
• No claim form available yet — do not attempt to file a claim through third-party websites before the official claim portal opens at mylansecuritieslitigation.com. Monitor the official site and contact JND Legal Administration at 1-888-383-0351 or [email protected] for updates.
• Once preliminary approval is granted, class notices will be mailed to all identified class members — typically within 30–60 days of the court order — and the official claim filing window will open.

What Is the Mylan Quality Control Securities Lawsuit About?

The Public Employees’ Retirement System of Mississippi and other investors filed a securities class action in the U.S. District Court for the Western District of Pennsylvania against Mylan N.V. and several former company executives. The lawsuit alleged Mylan violated Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by making materially false and misleading statements to investors about the quality control practices and regulatory compliance at its Morgantown, West Virginia pharmaceutical manufacturing facility — one of Mylan’s largest generic drug production sites in the United States.

Mylan’s Morgantown facility manufactures hundreds of generic drug products and is subject to regular inspections by the U.S. Food and Drug Administration (FDA). The lawsuit alleged that during the class period, Mylan manipulated quality control test results, misrepresented the integrity of its manufacturing compliance systems, and concealed significant regulatory risks from investors — allowing Mylan’s stock price to trade at artificially inflated levels. When the truth about the quality control deficiencies began to emerge, the stock declined, causing significant losses for investors who had purchased shares at the inflated prices.

According to the investors’ preliminary approval filing, the $60 million settlement represents a meaningful recovery relative to the class’s estimated recoverable damages, considering the significant litigation risks both sides faced. The settlement was reached following a December 2025 mediation session, after a July 2025 ruling in which the court denied Mylan’s motion for summary judgment — clearing the case to proceed toward trial.

How Is This Case Different from Other Mylan and Viatris Securities Cases?

Mylan and its successor Viatris have been defendants in multiple securities cases over the years. This is a separate and distinct $60 million settlement from all prior Mylan and Viatris cases. Here is how to distinguish them:

If you received a settlement notice about a Mylan or Viatris securities case in the past and already filed a claim, that was a different case. This new $60 million settlement covers investors in Mylan N.V. stock harmed by the alleged quality control manipulation at the West Virginia facility.

Who Is Likely to Qualify for a Payment?

While the specific class period has not yet been publicly confirmed in available sources as of this writing, the settlement class will generally include investors who:

• Purchased or acquired Mylan N.V. common stock during the class period as defined in the court-approved class notice.
• Suffered resulting damages — meaning the stock price declined due to the revelation of the alleged quality control misconduct, causing losses on shares purchased at the alleged artificially inflated prices.
• Are individuals, entities, funds, or institutions — both retail and institutional investors are typically eligible in securities class actions of this type.
• Have brokerage documentation confirming their Mylan N.V. stock transactions — including purchase dates, sale dates, prices paid, and shares held.

You likely do not qualify if:

• Your only Mylan-related holdings were through Viatris Inc. (VTRS) shares received in the 2020 Mylan/Upjohn merger — that is a different settled case.
• You only held Mylan options or derivatives rather than common stock, unless the plan of allocation specifically includes such instruments.
• Your calculated recognized loss falls below the minimum threshold (typically $10 in similar securities settlements).

Once preliminary approval is granted and the class notice is published, the exact class period, recognized loss formula, and eligibility criteria will be confirmed. Visit mylansecuritieslitigation.com for the official class definition when available.

How Much Can You Receive?

Specific payout details — including the recognized loss formula, estimated recovery per share, and plan of allocation — have not yet been published publicly as of this writing. These details will be included in the official class notice once the court grants preliminary approval.

In comparable pharmaceutical securities settlements of similar size, investors typically receive a pro rata share of the net settlement fund based on their recognized losses — calculated using the difference between the price paid for shares and either the price at which they were sold or a court-determined “true value” price after the corrective disclosures. Investors who held more shares and bought at higher prices generally receive larger payments.

Settlement fund breakdown (confirmed):

How to Prepare to File a Claim

Because the claim portal has not yet opened, here is what you should do right now to prepare:

Step 1 — Visit mylansecuritieslitigation.com and sign up for updates, or check the site regularly for the claim filing announcement.

Step 2 — Contact JND Legal Administration at 1-888-383-0351 or [email protected] to confirm whether you are on the class notice mailing list.

Step 3 — Gather your brokerage statements and transaction records for Mylan N.V. common stock now — you will need purchase dates, sale dates, number of shares, and prices paid for all transactions during the class period.

Step 4 — Contact your broker or financial advisor to request complete transaction history for your Mylan N.V. holdings if you do not have records readily available. Securities settlement administrators typically accept broker confirmation slips, account statements, or authorized broker letters.

Step 5 — Do not file claims through unofficial third-party sites before the official portal opens — only claims submitted through the official settlement website will be processed.

Step 6 — Once the official claim portal opens, file your claim promptly — do not wait until the last day in case technical issues arise.

Important Deadlines and Dates

Frequently Asked Questions

Do I need a lawyer to file a claim in this settlement? 

No. Once the claim portal opens at mylansecuritieslitigation.com, you can file your claim directly without hiring an attorney. Class counsel from Pomerantz LLP (Jeremy Lieberman, 212-661-1100) represents all class members at no individual cost. If you want independent advice about your specific investment losses, you may hire your own attorney at your own expense.

Is this Mylan $60M securities settlement legitimate?

 Yes. The settlement was filed with the U.S. District Court for the Western District of Pennsylvania on February 19, 2026, and reported by Law360. The official settlement website is mylansecuritieslitigation.com, administered by JND Legal Administration. Contact the administrator at 1-888-383-0351 or [email protected] to verify your information is on file.

When will claim deadlines be announced? 

Specific claim deadlines will be published after the court grants preliminary approval of the settlement — which typically takes several weeks to a few months from when the motion is filed. Once the court issues its preliminary approval order, JND Legal Administration will mail class notices to all identified investors and publish all deadlines on mylansecuritieslitigation.com. Check the site frequently for updates.

What if I miss the claim deadline once it is announced? 

In securities class actions, missing the claim deadline generally means you forfeit your right to receive any payment — even if you are a confirmed class member. Once deadlines are announced, set a calendar reminder well in advance. Do not wait until the last day.

Will this settlement payment affect my taxes? 

Securities fraud settlement payments are generally treated as a return of capital or capital gain depending on your individual tax situation and how the IRS classifies the specific damages. JND Legal Administration will issue appropriate tax forms once payments are distributed. Consult a qualified tax professional to understand how to report your payment on your federal and state tax returns.

Is Mylan still a public company I can trade? 

No. Mylan N.V. merged with Pfizer’s Upjohn division in November 2020 to form Viatris Inc. (NASDAQ: VTRS), which trades publicly today. This securities settlement covers investors who held Mylan N.V. shares during the class period — before or during that merger. Viatris Inc. is the successor entity that agreed to the $60 million settlement on behalf of Mylan N.V.

How is this case different from the old Mylan EpiPen securities case? 

The old In re Mylan N.V. Securities Litigation (Case No. 16-cv-7926, S.D.N.Y.) involved allegations about EpiPen Medicaid misclassification and generic drug price-fixing. That case was dismissed after the court granted Mylan’s summary judgment motion in March 2023. This new $60 million settlement involves a completely different set of allegations — specifically, quality control manipulation at Mylan’s West Virginia manufacturing plant — and is pending in the Western District of Pennsylvania, not New York.

What role did the Public Employees’ Retirement System of Mississippi play? 

The Public Employees’ Retirement System of Mississippi serves as the lead plaintiff in this case — meaning it filed and led the litigation on behalf of all class members. Under the Private Securities Litigation Reform Act (PSLRA), lead plaintiffs in securities class actions are typically large institutional investors with significant financial losses, which gives them the resources and incentive to pursue the case vigorously on behalf of all affected investors.

Sources and References

1. Official Settlement Website — mylansecuritieslitigation.com

Investors who held Mylan or Viatris shares and are researching other active pharmaceutical securities settlements may want to review the Celgene $239 million securities class action settlement covering investors who purchased Celgene stock between April 2017 and April 2018, with a claim deadline of April 13, 2026. If you purchased EpiPen products directly and want to understand your separate rights under the EpiPen antitrust litigation, our complete guide on Mylan and Pfizer EpiPen class action settlements — payments, eligibility, and what to do now in 2026 explains the current status of those separate cases.

Last Updated: March 18, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.

About the Author

Sarah Klein, JD, is a licensed attorney and legal content strategist with over 12 years of experience across civil, criminal, family, and regulatory law. At All About Lawyer, she covers a wide range of legal topics — from high-profile lawsuits and courtroom stories to state traffic laws and everyday legal questions — all with a focus on accuracy, clarity, and public understanding.
Her writing blends real legal insight with plain-English explanations, helping readers stay informed and legally aware.
Read more about Sarah